Latest news with #Pharmarack
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation
In one of the largest pharma deals in the domestic market in recent years, Ahmedabad-based Torrent Pharmaceuticals will acquire a controlling stake in investment firm KKR-backed JB Chemicals and Pharmaceuticals (known as JB Pharma) at an equity valuation of ₹25,689 crore, which will be followed by the merger of the two entities. The deal will be executed in two phases — acquisition of the 46.39 per cent stake held by KKR in JB Pharma at ₹1,600 per share, amounting to ₹11,917 crore, followed by a mandatory open offer to acquire up to 26 per cent of JB Pharma shares from public shareholders at ₹1,639.18 per share. 'In addition to the above, Torrent has also expressed its intent to acquire up to 2.8 per cent of equity shares from certain employees of JB Pharma at the same price per share as KKR,' the company said in a statement on Sunday. The next step in the deal will be a merger between Torrent Pharma and JB Pharma through a scheme of arrangement, under which every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharma. The boards of directors of both companies have approved this arrangement. KKR had acquired 54 per cent of JB Pharma in July 2020 from the promoters and founders, the Mody family, for approximately ₹3,100 crore (or ₹745 per share). It sold a part of its stake in March this year through block deals for ₹1,459.8 crore. KKR has earned more than five times on its investment, with around 36 per cent gross IRR. For instance, Torrent Pharma has previously indicated plans to increase its medical representative (MR) strength by 23 per cent by the end of FY26, and the acquisition can aid in manpower augmentation. Torrent Pharma holds a 3.74 per cent share in the domestic market (according to Pharmarack, May 2025), while JB Pharma commands a 1.12 per cent share. Further, consolidation in key international markets is expected to offer greater scalability. Samir Mehta, executive chairman of Torrent Pharma, said they want to build on JB Pharma's heritage and platform for the future. 'Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint, offer immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market and builds a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Torrent has previously taken the inorganic route to grow its business and enter newer segments — in 2013, it acquired Elder Pharma's India-branded business; followed by the dermaceutical business of Zyg Pharma in 2015 and the API plant of Glochem Industries in 2016. Among other major deals, it bought the India-branded business of Unichem in 2017. Its last major acquisition was of skin-care products from Curatio Healthcare in 2022. Torrent Pharma is a highly domestic-focused company, drawing around 55 per cent of its consolidated revenues from the domestic formulations business. India sales grew by 13 per cent in FY25 to ₹6,393 crore. While the company has been outperforming industry growth in the domestic market, it is also planning to increase MR strength by 23 per cent by FY26-end. Torrent has a strong presence in the cardiovascular, gastrointestinal and neurology segments. JB too has prominent cardiac and gastro brands like Cilacar, Metrogyl and Rantac. Torrent is also working on launching GLP-1 products as a day-one launch in FY26. Analysts expect a 15 per cent sales CAGR in domestic formulations for Torrent Pharma over FY25–27. Gaurav Trehan, co-head of Asia Pacific and head of Asia Pacific private equity at KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies.' Nikhil Chopra, chief executive officer and whole-time director of JB Pharma, pointed out that over the past five years, the company has emerged as one of India's fastest-growing pharmaceutical players. 'We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organisations will unlock greater opportunities to enhance healthcare access across our markets,' Chopra said. JB Pharma posted 12 per cent revenue growth in FY25 to ₹3,918 crore, while its EBITDA rose 16 per cent to ₹1,087 crore, and PAT increased 19 per cent to ₹660 crore. Notably, KKR Private equity has invested $2 billion in India in 2024 and recently invested $600 million in Manipal Group via its private credit arm.
News18
16-06-2025
- Health
- News18
Indians Popped 163 Crore Bottles Of Health Supplements in May—Enough to Stack 75 Mount Everests
Last Updated: Data shows that the three largest categories—vitamins, nutraceuticals, and calcium supplements—account for over 80 per cent of the total nutritional market Indians consumed nearly 163 crore bottles or strips of nutritional health supplements in May, the latest data shows. Stacked one on top of another, this would rise 75 times higher than Mount Everest, or nearly 30,000 times the height of the Burj Khalifa, considering each bottle or strip is 15cm in average height or length. Syrups, capsules, and tablets made up the bulk of this consumption, reflecting a strong preference for easy-to-use formats. According to Pharmatrac data, India's nutritional market was valued at Rs 20,747 crore as of May 2025 and in quantity sales, it sold 162.97 crore units. 'The nutritional market has almost 1.4 times of what it was five years back. Vitamins, nutraceuticals and calcium products contribute to this market and its growth," Sheetal Sapale, vice-president, commercial, at Pharmarack told News18. 'If one looks at the quantity consumption, the market does not show any seasonality pattern. This indicates a general increase in demand over the years, rather than a season or disease condition-driven consumption pattern." The data shows that the three largest categories—vitamins, nutraceuticals, and calcium supplements—account for over 80 per cent of the total nutritional market. The rest includes anti-oxidants, mineral supplements, appetite stimulants, biotin and combinations and caloric solutions. According to Dr Sumit Ray, medical director at Delhi-based Holy Family Hospital, the rise in multi-vitamin sales can be attributed to both lifestyle changes and dietary gaps. 'The increase in the sale of vitamins is probably due to a combination of factors. One is more awareness of health and fitness needs among the middle and upper class. The other reason is an increasing intake of fast food ordered through online food delivery platforms, leading to less balanced and nutritious diets, which may lead to more deficiencies". Also, Ray noticed that 'there is increased drive by the pharmaceutical industry to advertise and push the sales of these products, looking at what's called the 'wellness' market". What was once a supplementary or therapeutic product category seems to have now turned into a lifestyle mainstay. Over the last three years, many top pharma and FMCG players have entered or aggressively expanded into this space. These include Tata Consumer (with Tata GoFit), Micro Labs (Micro Wellness) P&G (Centrum), Nestlé–Dr. Reddy's joint venture, Cipla Health (Endura Mass), HUL (OZiva, Wellbeing Nutrition), among many others. From Doctor's Desk To Daily Habit What was once the domain of prescriptions has now become a household norm. 'Vitamin, minerals and calcium tablets have quietly found their spot, often on top of the fridge or bedside in Indian homes, no longer seen as doctor-only advice but woven into daily routines and also easily available online," said Dr Maninder Dhaliwal, an expert in paediatric pulmonology at NCR-based Amrita Hospital. Analysing the sales of the segment, Dr Rajeev Jayadevan, chairman, research cell, Kerala State's Indian Medical Association (IMA), noted a shift in user preference toward targeted formulations. 'The sales of vitamins and minerals are trending to favour more targeted supplements such as those purportedly designed for specific purposes like bone health, ageing, hair loss, memory and beauty enhancement," he said. The latest data shows that the vitamins, minerals and nutraceuticals sustained volume-led growth with particular combination drugs such as calcium with calcitriol and L-Methylfolate and L-Methylfolate with methycobalamin and pyridoxine. While the first combination is used for bone health, nerve support, and correction of nutritional deficiencies, the second helps to treat neuropathy, anaemia, and heart health. This shows, Jayadevan said, as the profile of users changes over the years, there appears to be diminishing interest in non-specific, plain supplements such as 'B-complex vitamins", which were popular many years ago. 'In the US, the supplement industry has such a strong hold that even perfectly healthy individuals commonly purchase them without a medical indication. India is likely to follow in that direction." However, Dhaliwal cautioned against blind consumption driven by trends. 'Here's the honest truth, we ideally should not be swallowing these supplements just because a social media reel says it's 'life-changing.' We should be listening to our bodies, reading our labs and talking to doctors." First Published: June 16, 2025, 13:01 IST News india Indians Popped 163 Crore Bottles Of Health Supplements in May—Enough to Stack 75 Mount Everests
&w=3840&q=100)
Business Standard
15-06-2025
- Health
- Business Standard
Anti-infective drug sales surge in May as fever season grips country
Analysts indicate sales in the segment are expected to grow more during monsoon months premium Sanket Koul New Delhi Listen to This Article Sales of anti-infective drugs in India grew 7.6 per cent year-on-year (Y-o-Y) to ₹2,130 crore in May 2025, up from ₹1,979 crore in the same month last year, driven by the onset of the viral season and a rise in Covid-19 cases, according to analysts and medical experts. Within the anti-infective segment—which accounts for about 11 per cent of total Indian Pharma Market (IPM) revenue—sub-groups such as antibacterials and antifungals led growth, with sales rising 9.1 per cent and 7 per cent, respectively, in May. Data from market research firm Pharmarack shows antibacterial sales increased from ₹1,676 crore in May
Time of India
10-06-2025
- Health
- Time of India
Sales of diabetes & cardiovascular drugs up 50% in Guj in two years
Ahmedabad: Gujarat is battling an uphill struggle with lifestyle diseases. Sales of drugs used to manage cardiovascular diseases and diabetes have shot up by at least 50% in the past two years, suggesting both a growing disease burden and increased patient compliance. According to data intelligence platform Pharmarack, the moving annual total (MAT) for cardiac therapy drugs stood at Rs 1,632 crore as of May 2025, marking a 44.4% rise from Rs 1,130 crore recorded in May 2023. The corresponding figure for anti-diabetic therapy rose even more sharply, increasing by 55.5% from Rs 688 crore to Rs 1,070 crore during the same period. MAT is a rolling calculation of sales value over the previous 12 months, and analysts say the consistent uptick highlights a worrying rise in non-communicable diseases driven by sedentary lifestyle, poor diets and mounting stress levels, particularly in urban areas. According to experts, while the surge in sales is partly due to higher detection and treatment adherence, it also reflects the underlying rise in incidence. Sheetal Sapale, vice-president-commercial, Pharmarack, said, "The rise in incidence is definitely seen, especially among the younger age group. People in their 30s and 40s are now being increasingly diagnosed with chronic conditions that were earlier associated with ageing populations. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Nagelpilz-Innovation: Dieses Lasergerät ist ein Wunder Heilratgeber Weiterlesen Undo Poor lifestyle is the key culprit here. Moreover, with more young people succumbing to cardiovascular diseases, the awareness has also grown substantially, because of which early diagnosis is taking place. Obesity is another key factor responsible for the higher incidence of diabetes as well as cardiac ailments." Increased awareness, early diagnosis and improved access to care have also contributed to the jump in drug consumption. Several doctors say that more patients are now opting for continuous medication to manage conditions proactively, rather than waiting for complications to arise. Doctors, however, warn that dietary habits also need to change. "The Indian diet is predominantly carbohydrate-heavy and deficient in protein as well as fibre. There is a rise in the consumption of processed foods which are easily available through quick-commerce apps as well as food aggregators. Obesity in children is becoming increasingly common because of processed and sugary food being consumed by them. These invitations to conditions like diabetes and hypertension and other cardiac ailments," said Dr Manoj Vithalani, a physician and medical expert. Environmental pollution is also a key factor responsible for poor heart health, according to Dr Vithalani. City-based physicians said that lifestyle related diseases and conditions are on rise steadily primarily due to sedentary lifestyle, excessive screen consumption, outside foods and lack of exercise. The most common symptoms – which are often overlapping – include hypertension, diabetes, and obesity, they added. Dr Ramesh Goyal, a senior endocrinologist with Apollo Hospitals, said that there has been a rise in awareness about Type 2 diabetes and thus there will be relatively more patients than 2023. "Two specific classes of medications - SGLT2 inhibitors and GLP-1 receptor agonists – are more acceptable by the practitioners and may have seen a rise in the overall mix. As diabetes is an overlapping condition, it is possible that the patients are also on other medications," he added.
Time of India
10-06-2025
- Health
- Time of India
Sale of cardiovascular drugs up 44%, anti-diabetic drugs up 55% in two years in Gujarat
Ahmedabad: Gujarat faces a growing struggle with lifestyle diseases, as evidenced by increasing sales of medications associated with the treatment of certain conditions. Sales of drugs used to manage cardiovascular diseases and diabetes have shot up by around 44% and 55% respectively in the past two years, suggesting a growing disease burden and increased patient compliance. Tired of too many ads? go ad free now According to data intelligence platform Pharmarack, the moving annual total (MAT) for cardiac therapy drugs stood at Rs 1,632 crore as of May 2025, marking a 44.4% rise from Rs 1,130 crore recorded in May 2023. The corresponding figure for anti-diabetic therapy rose even more sharply, increasing by 55.5% from Rs 688 crore to Rs 1,070 crore during the same period. MAT is a rolling calculation of sales value over the previous 12 months, and analysts say the consistent uptick highlights a worrying rise in non-communicable diseases driven by sedentary lifestyle, poor diets and mounting stress levels, particularly in urban areas. According to experts, while the surge in sales is partly due to higher detection and treatment adherence, it also reflects the underlying rise in incidence. Sheetal Sapale, vice president-commercial, Pharmarack, said, "Rise in incidence is definitely seen, especially among the younger age group. People in their 30s and 40s are now being increasingly diagnosed with chronic conditions that were earlier associated with ageing populations. Poor lifestyle is the key culprit here. Moreover, with more young people succumbing to cardiovascular diseases, the awareness has also grown substantially, because of which early diagnosis is taking place. Obesity is another key factor responsible for the higher incidence of diabetes as well as cardiac ailments." Increased awareness, early diagnosis and improved access to care have also contributed to the jump in drug consumption. Tired of too many ads? go ad free now Several doctors say that more patients are now opting for continuous medication to manage conditions proactively, rather than waiting for complications to arise. Doctors, however, warn that dietary habits also need to change. "The Indian diet is predominantly carbohydrate-heavy and deficient in protein as well as fibre. There is a rise in the consumption of processed foods which are easily available through quick-commerce apps as well as food aggregators. Obesity in children is becoming increasingly common because of processed and sugary food being consumed by them. These invitations to conditions like diabetes and hypertension and other cardiac ailments," said Dr Manoj Vithalani, a physician and medical expert. Environmental pollution is also a key factor responsible for poor heart health, according to Dr Vithalani.
